No Data
CRL Stock May Benefit From New Neuroscience Research Collaboration
SI-BONE (NASDAQ:SIBN Shareholders Incur Further Losses as Stock Declines 8.8% This Week, Taking Three-year Losses to 33%
Morgan Stanley Maintains Si-Bone(SIBN.US) With Buy Rating, Maintains Target Price $19
Morgan Stanley analyst Drew Ranieri maintains $Si-Bone(SIBN.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 39.8% and a
Buy Rating Justified: SI-Bone's Growth Potential and Market Expansion Opportunities
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 40.3%: Read This Before Placing a Bet
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System